In acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), MultiDrug Resistance (MDR) protein function measured in leukocytes correlates with disease prognosis (prognostic marker) and inefficiency of certain therapies (predictive marker). Moreover, MDR protein function is an independent biomarker in AML. The measurement of the functional activity of MDR1, MRP1 and BCRP with the SOLVO MDQ KitTM allows patient risk stratification and can help choose a tailored treatment strategy contributing to better patient outcome and quality of care.

For more detailed information, please download our flyer!